When people have Alzheimer’s disease, their brains slowly accumulate abnormal clumps of two proteins: amyloid and tau. At ...

Each episode of this journey through a disease state contains both a physician guide and a downloadable/printable patient ...

With early diagnosis of Alzheimer's disease comes the possibility of treatment to not only help manage symptoms but also slow ...

Eli Lilly has chalked up another regulatory approval for its anti-amyloid therapy for Alzheimer's disease, Kisunla, in China – the world's second-largest pharma market. The National Medical ...

Eisai and Biogen's Alzheimer's therapy Leqembi will be ... The US regulator has granted accelerated approval to anti-amyloid therapy Leqembi (lecanemab) with a fairly broad label to treat patients ...

Loss of brain volume in people with Alzheimer's disease reflects neurodegeneration. In their Personal View, Christopher R S Belder and colleagues 3 propose a re-interpretation of volume changes in the ...

Low-level light therapy, also called photobiomodulation (PBM), has emerged as a promising approach to Alzheimer's treatment, ...

Two hundred thousand Americans develop Alzheimer’s ... of a causal role for amyloid. Skeptical biologists have proposed alternative mechanisms for the effects of anti-amyloid agents, suggesting ...

The findings could open the door to testing anti-amyloid therapies in FTD patients with plaques ... “It now seems possible to use [plasma p-Tau217] to track the Alzheimer component of any progressive ...

A new pilot study known as STAMINA (Senolytics To Alleviate Mobility Issues and Neurological Impairments in Aging), that focused on the effects of senolytic medications, Dasatinib and Quercetin (DQ), ...